<DOC>
	<DOCNO>NCT00516724</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose drug KU-0059436 give combination carboplatin and/or Paclitaxel chemotherapy</brief_summary>
	<brief_title>Study Assess Safety Tolerability PARP Inhibitor Combination With Carboplatin and/or Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Male female patient histologically cytologically diagnose malignant solid tumour Adequate bone marrow , hepatic renal function Performance status 2 ( ECOG scale ) . Any chemotherapy , radiotherapy ( except palliative ) , endocrine immunotherapy within 4 week prior entry Major surgery 4 week enter study must recover effect major surgery More two previous course platinumcontaining chemotherapy Heavily pretreated patient ( &gt; 2 course previous chemotherapy and/or extensive irradiation lead bone marrow deficiency ) exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>malignant solid tumour</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
</DOC>